Mark P. Schoenberg's most recent trade in UroGen Pharma Ltd was a trade of 3,686 Ordinary Shares done at an average price of $19.7 . Disclosure was reported to the exchange on Feb. 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 03 Feb 2026 | 3,686 | 144,985 (0%) | 0% | 19.7 | 72,577 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 03 Feb 2026 | 1,844 | 150,514 (0%) | 0% | 19.7 | 36,308 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 03 Feb 2026 | 1,843 | 148,671 (0%) | 0% | 19.7 | 36,289 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2026 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 6,666 | 152,358 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 6,666 | 13,334 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 3,334 | 142,359 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 3,334 | 0 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 3,333 | 145,692 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 3,333 | 3,334 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 19 Nov 2025 | 10,000 | 139,025 (0%) | 0% | 25 | 250,000 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2025 | 1,667 | 1,667 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2025 | 1,667 | 149,896 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.11 per share. | 07 Sep 2025 | 871 | 149,025 (0%) | 0% | 19.1 | 16,645 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.69 per share. | 11 Aug 2025 | 10,000 | 148,229 (0%) | 0% | 17.7 | 176,900 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2025 | 10,000 | 163,378 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.14 per share. | 28 Jul 2025 | 5,149 | 158,229 (0%) | 0% | 19.1 | 98,552 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2025 | 10,000 | 158,540 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2025 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.37 per share. | 08 Jun 2025 | 5,162 | 153,378 (0%) | 0% | 7.4 | 38,044 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 3,333 | 148,999 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 3,333 | 150,436 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 3,333 | 3,334 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 3,333 | 6,667 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 1,896 | 147,103 (0%) | 0% | 11.1 | 21,121 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 1,896 | 148,540 (0%) | 0% | 11.1 | 21,121 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 1,334 | 146,425 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 1,334 | 0 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 759 | 145,666 (0%) | 0% | 11.1 | 8,455 | Ordinary Shares |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 1,666 | 145,950 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 1,666 | 3,334 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Mark P. Schoenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.08 per share. | 09 Sep 2024 | 859 | 145,091 (0%) | 0% | 13.1 | 11,236 | Ordinary Shares |